Read Chr. Hansen Annual Report 08/09

• 10.0% organic growth in revenue to EUR 511 million
• EBITDA before special items increased by 9.4% to EUR 155 million
• EBITDA margin was 30.3%
• Free cash flow more than doubled to EUR 78 million
• Expected continued growth for 2009/10

”We are extremely satisfied that during challenging times we are able to not only grow our revenue and gain market shares but also to increase our earnings - and not least our ability to generate liquidity,” says Lars Frederiksen, CEO.

”It is especially satisfactory that our sales growth covers both products and markets. We have created a strong and growth driven company based on a solid bioscience platform,” he adds.